scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
企業コードSCPH
会社名scPharmaceuticals Inc
上場日Nov 17, 2017
最高経営責任者「CEO」Mr. John H. Tucker
従業員数162
証券種類Ordinary Share
決算期末Nov 17
本社所在地25 Burlington Mall Road, Suite 203
都市BURLINGTON
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号01803
電話番号16175170730
ウェブサイトhttps://www.scpharmaceuticals.com/
企業コードSCPH
上場日Nov 17, 2017
最高経営責任者「CEO」Mr. John H. Tucker
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし